Indivior Pharmaceuticals Inc (INDV)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Indivior Pharmaceuticals Inc Stock (INDV) Company Profile

Indivior Pharmaceuticals Inc

Healthcare (1052)

804-379-1090

10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD

Prossima data di guadagno

Ultimi documenti SEC

INDV's Discussions on Twitter

Compare INDV vs TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INDV Indivior Pharmaceuticals Inc	33.20	3.92B	1.29B	251.00M	-193.86M	1.9744
TAK Takeda Pharmaceutical Co Adr	19.75	63.08B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.67	48.60B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	10.12	44.53B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.44	32.83B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	542.11	23.25B	3.17B	1.29B	1.01B	27.09

Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-06-18	Iniziato	Barclays	Overweight
2025-08-06	Iniziato	H.C. Wainwright	Buy
2025-07-22	Ripresa	Jefferies	Buy
2025-01-28	Iniziato	Rodman & Renshaw	Buy
2024-07-23	Iniziato	Piper Sandler	Overweight
2024-04-03	Iniziato	Craig Hallum	Buy
2023-07-13	Iniziato	Northland Capital	Outperform

Mostra tutto

Indivior Pharmaceuticals Inc Borsa (INDV) Ultime notizie

Indivior Pharmaceuticals Inc Azioni (INDV) Dati Finanziari

Indivior Pharmaceuticals Inc Azioni (INDV) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Anderson Woodrow D	Chief Accounting Officer	Aug 05 '26	Buy	36.28	1,500	54,420	26,138
Heidbreder Christian	Chief Scientific Officer	Jul 10 '26	Sale	41.14	18,586	764,628	209,337
Heidbreder Christian	Officer	Jul 10 '26	Proposed Sale	41.14	18,586	764,628	0
Heidbreder Christian	Officer	Jun 11 '26	Proposed Sale	38.06	18,586	707,383	0
Heidbreder Christian	Chief Scientific Officer	Jun 11 '26	Sale	38.06	18,586	707,383	227,923
Preblick Ryan	Chief Financial Officer	Jun 08 '26	Sale	37.70	36,000	1,357,200	284,751
Preblick Ryan	Officer	Jun 08 '26	Proposed Sale	37.70	36,000	1,357,200	0
Ryan Barbara	Director	Mar 13 '26	Buy	31.09	8	249	5,724
Ryan Barbara	Director	Mar 09 '26	Buy	32.56	31	1,009	5,716
Kingsley Stuart A	Director	Mar 06 '26	Buy	31.86	940	29,953	5,582

Indivior Pharmaceuticals Inc (INDV)

Indivior Pharmaceuticals Inc Stock (INDV) Company Profile

Compare INDV vs TAK, TEVA, HLN, ZTS, UTHR

Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades

Indivior Pharmaceuticals Inc Borsa (INDV) Ultime notizie

With 77.27% of shares represented, Indivior (INDV) stockholders vote on merger-related share issuance. - Stock Titan

A $1B special dividend features in Indivior (INDV)'s revised merger valuation details. - Stock Titan

Indivior stock pre-market at EUR 32.10: plus 0.00 percent - AD HOC NEWS

Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth - GlobeNewswire Inc.

Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.

Three parties report a passive holding above 5% in Indivior (INDV). - Stock Titan

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - Business Wire

Indivior (NASDAQ: INDV) Announces Conditional $8.13 Special Dividend Pending Merger Completion - Kalkine Media

Indivior Declares $8.13 Per Share Special Dividend Tied to Supernus Merger Closing - Minichart

An $8.13 cash payout at Indivior (INDV) hinges on a merger closing - Stock Titan

Indivior declares $8.13 special dividend contingent on merger - Investing.com India

Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend - Indivior

Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing - Quiver Quantitative

Indivior declares $8.13 special dividend contingent on merger - Investing.com

$1 billion dividend hangs on Supernus (NASDAQ: SUPN) merger vote - Stock Titan

Indivior stock gains as Supernus merger and special dividend plan come into focus - ad-hoc-news.de

Indivior (INDV) plans special dividend if Supernus merger closes, with two payout structures - Stock Titan

SUPN: Strong CNS portfolio growth, innovative pipeline, and Indivior merger set to drive future expansion - TradingView

Indivior stock gains on raised 2026 guidance and Supernus deal - ad-hoc-news.de

Indivior stock rises on strong Q2 2026 earnings and higher full-year guidance - AD HOC NEWS

Indivior stock gains on raised 2026 outlook and strong Sublocade growth - AD HOC NEWS

Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Price to earnings forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView

Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indiv - The National Law Review

INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent

Indivior stock trades below fair value as latest earnings beat expectations - AD HOC NEWS

Why Indivior Pharmaceuticals (INDV) Is Back In The Spotlight - sahmcapital.com

Indivior Pharmaceuticals CAO Woodrow D. Anderson Acquires 1,500 Shares at $35.69 Each - Kalkine Media

Indivior (INDV) accounting chief adds 1,500 shares in market or private buy - Stock Titan

Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan - Yahoo Finance

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Barchart.com

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Yahoo Finance

Should Investors Buy INDV as Sublocade Growth Meets Rising Risks? - Yahoo Finance

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - theglobeandmail.com

Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.3% -- GF Value Says Still Overvalued - GuruFocus

Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - ad-hoc-news.de

Indivior stock edges higher as options activity and analyst targets point to further upside - Ad-hoc-news.de

Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm

Indivior Q2 2026 Earnings Call: Complete Transcript - Benzinga

Indivior (INDV) Gains 2.07% to $39.01 as Opioid Addiction Treatment Demand Lifts Pharma StockBreakout Trade - vinanet.vn

Indivior Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:INDV - TradingView

Is Indivior Pharmaceuticals (INDV) Below Fair Value Despite A 194% Return? - webull.com

Indivior Pharmaceuticals, Inc. Revenue Breakdown – FWB:E7P - TradingView

Oaktree trims Indivior (INDV) holdings, files Schedule 13D exit amendment - Stock Titan

Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada

Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis

Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance

Indivior Plc (INDV) News, Articles, Events & Latest Updates - Stocktwits

Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st

Indivior Pharmaceuticals Inc Azioni (INDV) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Indivior Pharmaceuticals Inc Azioni (INDV) insider trading

Simile a INDV